Transformants (e.g., Recombinant Dna Or Vector Or Foreign Or Exogenous Gene Containing, Fused Bacteria, Etc.) Patents (Class 435/252.3)
  • Patent number: 11118171
    Abstract: The invention discloses a recombinant Corynebacterium glutamicum for producing lysine by biofilm continuous fermentation and a construction method thereof, wherein the recombinant Corynebacterium glutamicum is constructed by overexpressing a protease gene FtsH in a Corynebacterium glutamicum; and the construction method comprises the following steps of: (1) performing PCR on a genome of the Corynebacterium glutamicum, and amplifying the FtsH gene to obtain an amplified FtsH gene segment; (2) cloning the FtsH gene segment to an overexpression plasmid to obtain a recombinant plasmid; and (3) introducing the recombinant plasmid into the Corynebacterium glutamicum, and screening to obtain the recombinant Corynebacterium glutamicum.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: September 14, 2021
    Assignee: Nanjing Tech University
    Inventors: Hanjie Ying, Dong Liu, Yong Chen, Qingguo Liu, Pingkai Ouyang, Ming Lei, Huanqing Niu, Bin Yu, Di Zhang, Yuhan Yang, Shishi Wu
  • Patent number: 11103568
    Abstract: Immunogenic composition are provided comprising PnCo and/or GlpO polypeptides identified as being preferentially expressed during the virulent phase of an infection related to streptococcal bacteria. The compositions can be used for eliciting immune response against streptococcal infections, such as against infections caused by S. pneumoniae.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: August 31, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Blaine Pfeifer, Charles Jones, Jonathan Lovell
  • Patent number: 11091782
    Abstract: Non-naturally occurring Zymomonas strains useful for the production of 2,3-butanediol are provided.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: August 17, 2021
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: Min Zhang, Yat-Chen Chou, Mary Ann Franden, Michael E. Himmel
  • Patent number: 11083787
    Abstract: The application describes recombinant BoHV-1 triple mutant viruses that express protective antigens of other bovine respiratory viruses associated with Bovine respiratory disease complex (BRDC).
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 10, 2021
    Assignee: Board of Supervisors of the Louisiana State University and Agricultural and Mechanical College
    Inventor: Shafiqul I. Chowdhury
  • Patent number: 11066456
    Abstract: The present invention provides TREM2 constructs. TREM2 constructs of the invention are polynucleotide sequences encoding a polypeptide, wherein the polypeptide comprises at least one TREM2 or fragment thereof and a targeting moiety and optionally comprising a signal peptide and/or a purification moiety. The present invention also provides isolated polypeptides encoded by TREM2 constructs, vectors comprising TREM2 constructs, isolated cells comprising said vectors, and methods of use thereof.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 20, 2021
    Assignee: Washington University
    Inventors: Marco Colonna, Yarning Wang, Marina Celia
  • Patent number: 11066465
    Abstract: Provided herein are anti-VEGF-A antibodies and antibody conjugates thereof. Some embodiments of the antibodies can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy. Further provided are methods for conjugation of a polymer to a protein such as an antibody, such as IgG1.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: July 20, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Wah Yuen To, Hong Liang
  • Patent number: 11065296
    Abstract: In various embodiments, a pharmaceutical composition comprising an effective amount of a peptide having the amino acid sequence represented by Formula (I) or an analog thereof, and a pharmaceutically tolerable excipient is described. In some embodiments, the analog of the peptide of Formula (I), comprises the peptide sequence of Formula (I) wherein one or more of the amino acids residues are modified by a) C-terminal modification; b) D-amino acid substitution; and/or c) deletion of one or more amino acid residues. A method of inhibiting the growth of a microorganism comprising contacting the microorganism in a medium with an effective amount of the peptide of Formula (I) or an analog thereof is also described, as are similar methods of treating a disease or disorder associated with microbial activity in a subject by administering an effective amount of a peptide of Formula (I) or an analog thereof and a pharmaceutically tolerable excipient to the subject.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: July 20, 2021
    Assignee: City University of Hong Kong
    Inventors: Yun Wah Lam, Doris Wai Ting Au, Hongyan Sun
  • Patent number: 11046936
    Abstract: The present application provides engineered polypeptides having imine or oxime reductase activity, polynucleotides encoding the engineered polypeptides, host cells capable of expressing the engineered polypeptides, and methods of using these engineered polypeptides with a range of ketone amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: June 29, 2021
    Assignee: Codexis, Inc.
    Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Melissa Ann Mayo, Stephan Jenne, Auric Anthony Sowell-Kantz, Carmela Molinaro
  • Patent number: 11046735
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: June 29, 2021
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Michelle Leslie
  • Patent number: 11040086
    Abstract: An active peptide for enhancing the phagocytic functions of retinal pigment epithelium and a use thereof, which belongs to the technical field of preparing drugs for treating retinal neurodegenerative diseases, are described. The amino acid sequence of the active peptide for enhancing the phagocytic functions of retinal pigment epithelium described in the disclosure was as shown in SEQ ID NO.1. The active peptide of the present invention has biological characteristics similar to those of Gas6 full-length proteins, with an effect of enhancing the phagocytic functions of retinal pigment epithelium.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 22, 2021
    Assignee: Beijing Tongren Hospital, Capital Medical University
    Inventors: Jingxue Zhang, Shen Wu, Ningli Wang
  • Patent number: 11041003
    Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: June 22, 2021
    Assignee: The Texas A&M University System
    Inventors: Magnus Hook, Ya-Ping Ko, Emanuel Smeds, Vannakambadi K. Ganesh
  • Patent number: 11035011
    Abstract: A method for identifying a risk factor for diseases, disorders or conditions, such as those caused by human immunodeficiency virus, using the polymerase chain reaction and specific primers. Methods for treating patients having these diseases, disorders or conditions by antimicrobial treatment of the risk factor by combined antiviral and antibacterial treatment or by sustaining or stimulating the subject's immune system. Methods for screening biological products including red blood cell preparations. Primers and methods for detecting nucleic acids or microbial agents associated with red blood cells, such as those associated with red blood cells in subjects infected with HIV and undergoing antiretroviral therapy.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 15, 2021
    Inventor: Luc Montagnier
  • Patent number: 11027004
    Abstract: This invention relates to outer membrane vesicles (OMVs) from Gram-negative bacteria. The vesicles comprise heterologous proteins or immunogenic fragments thereof expressed as lipoproteins in their membrane. The OMVs of the invention are capable of eliciting an immune response to the heterologous protein or to a fragment thereof when administered to a mammal. Other aspects of the invention relate to methods of preparing the OMVs and immunogenic compositions containing the same.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 8, 2021
    Assignee: BIOMVIS SRL
    Inventors: Guido Grandi, Laura Fantappie', Carmela Irene
  • Patent number: 11028144
    Abstract: A soluble polypeptide comprising a modified glycoprotein V (GPV) lacking a functional transmembrane domain for use in the treatment or prevention of a thrombotic disease in a subject, said treatment or prevention comprising administering to the subject an effective amount of said soluble polypeptide.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: June 8, 2021
    Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG
    Inventors: Bernhard Nieswandt, Sarah Beck, David Stegner
  • Patent number: 11008534
    Abstract: A bacteria referred to here as Bacillus subtilis 6A-1 is provided, compositions thereof and processes for use of the bacteria, spores, cells, extracts and enzymes. The compositions which comprise the bacteria, spores, cells, extracts and/or enzymes are capable of degrading polysaccharides. Such compositions are capable of degrading cellulose, including plant-produced cellulose, microcrystalline cellulose and carboxymethyl cellulose. The bacteria produces at least two cellulose-degrading protein fractions. Cellulose degrading activity continues across pH2 to pH13.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 18, 2021
    Assignee: AGRI-KING, Inc.
    Inventors: Gbenga Ayangbile, Mary Grzemski, James F. Tobey, Jr., David Spangler, Lucas Krueger
  • Patent number: 11002746
    Abstract: Disclosed is a blood analyzer that includes: a sample preparation unit configured to mix a blood specimen and a fluorescent dye for staining nucleic acid to prepare a measurement sample; a light receiver configured to receive fluorescence and scattered light that are generated by light being applied to the measurement sample prepared by the sample preparation unit; and a controller programmed to determine whether or not infection with Plasmodium has occurred, on the basis of a value representing variation of a distribution of first particles in a range where single-ring form of red blood cells appear, the range where single-ring form of red blood cells appear being identified according to fluorescence intensities and scattered light intensities obtained by processing of signals from the light receiver.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: May 11, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Yuhgi Suzuki, Takuma Watanabe
  • Patent number: 10995322
    Abstract: Genetically modified isopropylmalate synthases, processes for preparing a C7-C11 2-ketoacids utilizing genetically modified isopropylmalate synthases, and microbial organisms including genetically modified isopropylmalate synthases are described. The genetically modified isopropylmalate synthases, processes for preparing a C7-C11 2-ketoacids, and microbial organisms including genetically modified isopropylmalate synthases can be particularly useful for producing corresponding Cn_1 aldehydes, alcohols, carboxylic acids, and Cn_2 alkanes both in vivo and in vitro.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: May 4, 2021
    Assignee: Dow Global Technologies LLC
    Inventors: Paresh C. Sanghani, Sarah Delaplane
  • Patent number: 10988745
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 27, 2021
    Assignee: RESOLVE THERAPEUTICS, LLC
    Inventors: James Arthur Posada, Chris Gabel
  • Patent number: 10988599
    Abstract: This invention relates to the field of producing bioplastics. Specifically, it relates to a method of producing all key ingredients of bioplastic making from pumpkins and making of bioplastic with these ingredients. More specifically, glycerin and other chemicals are extracted from pumpkin seed oil and mixed with starches that in the pumpkin flesh and then reinforced with pumpkin fibers to make bioplastic. The bioplastic produced with the method as disclosed in this invention possess superior properties in tensile strength and biodegradability compared to bioplastic made with petroleum derived glycerin.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 27, 2021
    Inventor: Kaien Yang
  • Patent number: 10980893
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: April 20, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Patent number: 10975122
    Abstract: The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor B-I, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 13, 2021
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Nathan Karin, Gizi Wildbaum
  • Patent number: 10960049
    Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: March 30, 2021
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Patent number: 10947570
    Abstract: Disclosed are methods for regulating biosynthesis of at least one of pimelic acid, 7-aminoheptanoic acid, 7-hydroxyheptanoic acid, heptamethylenediamine, 7-aminoheptanoland 1,7-heptanediol (C7 building blocks) using a pathway having a pimeloyl-ACP intermediate, the method including the step of downregulating the activity of BioF. Also disclosed are recombinant hosts by fermentation in which the above methods are performed. Further disclosed are recombinant hosts for producing pimeloyl-ACP, the recombinant host including a deletion of a bioF gene.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: March 16, 2021
    Assignee: INV Nylon Chemicals Americas, LLC
    Inventors: Alexander Brett Foster, Stephen Thomas Cartman, Jonathan Kennedy
  • Patent number: 10946105
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 16, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Patent number: 10927162
    Abstract: A mutant cytochrome protein originated from a cytochrome protein having three heme-binding domains, which mutant cytochrome protein lacks the first heme-binding domain and the second heme-binding domain as counted from the N-terminus, is provided. The mutant cytochrome protein may lack a region(s) containing the first and second heme-binding domains.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: February 23, 2021
    Assignees: ARKRAY, Inc., Ultizyme International Ltd.
    Inventors: Koji Sode, Junko Shimazaki, Kazushige Mori, Katsuhiro Kojima
  • Patent number: 10925986
    Abstract: The invention provides methods for microbial bioburden reduction of various chromatography matrices, including bioburden reduction in the context of large-scale Protein A-based affinity chromatography columns.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: February 23, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Nathan L. Mao, Wenbin Qi, Bernhard Schilling, Scott Carver
  • Patent number: 10898585
    Abstract: The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg/mL.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: January 26, 2021
    Assignees: PTC THERAPEUTICS .INC., NATIONAL TAIWAN UNIVERSTY
    Inventors: Mark Pykett, Richard Thorn, Wuh-Liang (“Paul”) Hwu
  • Patent number: 10894809
    Abstract: A novel technique for improving secretory production of a heterologous protein by coryneform bacteria is described, and thereby a method for secretory production of a heterologous protein is provided. A coryneform bacterium able to secrete a heterologous protein modified so that the activity of RegX3 protein is reduced is cultured to produce the heterologous protein by secretory production.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: January 19, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventors: Yumi Ito, Yoshihiko Matsuda
  • Patent number: 10888599
    Abstract: The invention relates to various compositions for improving exercise performance and/or recovery. The invention also relates to methods of using these compositions and kits including these compositions to improve exercise performance and/or recovery.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 12, 2021
    Assignee: Beachbody, LLC
    Inventors: Nima Alamdari, Michael Wilson, May Lam
  • Patent number: 10889842
    Abstract: The present disclosure relates to recombinant microorganisms engineered for enhance production of a desired amino acid, as well as related biomass, and compositions which are useful, inter alia, as animal feed ingredients. The present invention also provides related methods.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: January 12, 2021
    Assignee: CALYSTA, INC.
    Inventors: Renee M. Saville, Joshua A. Silverman, Eric G. Luning, Brandon D. Doss, Lorraine Joan Giver, Sol M. Resnick, Drew D. Regitsky
  • Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • Patent number: 10870680
    Abstract: A scorpion venom heat-resistant synthetic peptide (SVHRSP) contains an amino acid sequence of SEQ ID NO 1. One or more amino acids the amino acid sequence can be substituted or deleted. A pharmaceutical composition that contains the SVHRSP has numerous applications. The pharmaceutical composition can be used to protect neuronal cell against amyloid beta-induced toxic effects, or to inhibit the sodium channel current of a hippocampal neuronal cell, or to protect a neuronal cell against NMDA-induced injury. It may also promote the formation of a pluripotent neural stem cell from a type II astrocyte, or treats a subject, such as a human, having epilepsy, Alzheimer's disease, or Parkinson's disease.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: December 22, 2020
    Assignee: DALIAN MEDICAL UNIVERSITY
    Inventors: Jie Zhao, Shao Li, Wanqin Zhang
  • Patent number: 10844348
    Abstract: The present disclosure relates to a microorganism of the genus Corynebacterium producing 5?-xanthosine monophosphate and a method for producing 5?-xanthosine monophosphate using the same.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: November 24, 2020
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Min Ji Baek, Ji Hye Lee, Boram Lim, Byoung Hoon Yoon, Jeong Eun Lee, Su-bin Lim, Jaeho Jeong
  • Patent number: 10844099
    Abstract: The invention concerns novel streptavidin muteins. In one embodiment such a mutein (a) contains two or more mutations in the region of the amino acid positions 117 to 121 with reference to the amino acid sequence of wild type streptavidin of which amino acid residues 14 to 139 are as set forth at SEQ ID NO:212 and (b) has a higher binding affinity than each of (i) a streptavidin mutein “1” (SEQ ID NO: 16) that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: November 24, 2020
    Assignee: IBA GMBH
    Inventor: Thomas Schmidt
  • Patent number: 10828362
    Abstract: Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: November 10, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Klaus Linde, Anke Grosse-Herrenthey
  • Patent number: 10813995
    Abstract: The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 27, 2020
    Assignee: FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
    Inventors: Mariangela Figini, Alessandro Satta, Alessandro Massimo Gianni, Massimo Di Nicola
  • Patent number: 10809222
    Abstract: The present invention provides methods for fabricating field-effect devices and sensor arrays. The field of the invention also pertains to methods of using the sensors individually, in combination, and in array fashion to detect molecules. The present invention also provides for products produced by the methods of the present invention and for apparatuses used to perform the methods of the present invention.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 20, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Alan T. Johnson, Jin Xi, Ganghee Han, Mitchell Lerner, Jeffery G. Saven, Renyu Liu, Felipe Matsunaga, Jose Manuel Perez-Aguilar
  • Patent number: 10787691
    Abstract: A method for producing an L-amino acid such as L-glutamic acid is provided. An L-amino acid is produced by culturing in a medium a bacterium having an L-amino acid-producing ability, which has been modified so that the activity of a c1795 protein is reduced or the activity of a protein of which the expression is repressed by a c1795 protein is increased, and collecting the L-amino acid from the medium or cells of the bacterium.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: September 29, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Hiromi Noguchi, Yo Nishiyama, Yoshihiro Ito
  • Patent number: 10781989
    Abstract: The diffraction lens has an incident side and an exit side that are both convexly shaped, includes an exit diffraction plane that has an absolute value for the order of diffraction of 5 or greater and is disposed on the exit side, and is shaped such that the absolute value of a curvature at the surface apex of an envelope surface of the exit diffraction plane is smaller than the absolute value of a curvature at the surface apex of an incident surface, or the absolute value of the amount of sag in the direction of the optical axis at an outer periphery of the envelope surface of the exit diffraction plane is smaller than the maximum absolute value of the amount of sag in the direction of the optical axis at an outer periphery of the incident surface.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: September 22, 2020
    Assignee: MAXELL JOEI TECH CO., LTD.
    Inventor: Takeshi Shimano
  • Patent number: 10781241
    Abstract: The present invention relates to providing improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. Preferably, the iCP-SOCS3 recombinant protein may be used as protein-based anti-pancreatic cancer agent by utilizing the platform technology for macromolecule intracellular transduction.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: September 22, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Patent number: 10774391
    Abstract: The present invention relates to a recombinant bacterium based on a non-pathogenic bacterium that has a modified genome containing a nucleic acid of interest from a pathogen that is detected by a molecular diagnostic assay and that mimics the diagnostic profile of the pathogen. The invention further relates to a diagnostic control composition comprising the recombinant bacterium and to methods for producing the recombinant bacterium. The recombinant bacterium is a safe, reliable quality control for the detection of pathogens such as Mycobacterium tuberculosis and Staphylococcus aureus. The invention also relates to a kit comprising either the recombinant bacterium, compositions containing the recombinant bacterium or bacteria produced according to the method of the invention.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Bavesh Davandara Kana, Edith Erika Machowski
  • Patent number: 10765094
    Abstract: The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: September 8, 2020
    Assignees: TRANSGENIC INC., NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
    Inventors: Kenichi Yamamura, Takao Iwawaki, Daisuke Oikawa, Tomoo Ishikawa
  • Patent number: 10760107
    Abstract: The purpose of the present invention is to provide an organism having an ergothioneine productivity that is capable of easily producing ergothioneine within a short period of time at a high yield, as compared with a conventional technology, and, therefore, enables ergothioneine production on an industrial scale. This purpose can be achieved by a transformed fungus into which a gene encoding enzyme (1) or genes encoding enzymes (1) and (2) have been inserted and in which the inserted gene(s) are overexpressed. (1) an enzyme catalyzing a reaction of synthesizing hercynyl cysteine sulfoxide from histidine and cysteine in the presence of S-adenosyl methionine, iron (II) and oxygen. (2) An enzyme catalyzing a reaction of synthesizing ergothioneine from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: September 1, 2020
    Assignee: KIKKOMAN CORPORATION
    Inventors: Seiichi Hara, Keiko Kurosawa, Keiichi Ichikawa
  • Patent number: 10753944
    Abstract: The present invention relates to a method for covalently binding a cell surface protein and a ligand, the ligand being capable of specifically binding to the cell surface protein, the method consisting essentially of contacting the living cells expressing the cell surface protein with the ligand comprising at least one furan moiety, thereby covalently binding the cell surface protein and the ligand.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 25, 2020
    Assignee: UNIVERSITEIT GENT
    Inventors: Annemieke Madder, Christophe Ampe, Willem Vannecke, Marleen Van Troys
  • Patent number: 10752931
    Abstract: The invention further relates to a process for the enzymatic synthesis of an (oligo)peptide. The invention relates to a method for designing an enzymatic synthesis process of an (oligo)peptide, comprising identifying two or more (oligo)peptide fragments of an (oligo)peptide, which fragments are (oligo)peptides suitable for preparing the (oligo)peptide by enzymatic condensation of the two or more peptide fragments using a ligase. The invention relates to a method for designing an enzymatic synthesis process of a cyclic (oligo)peptide, comprising identifying a non-cyclic (oligo)peptide from which the cyclic (oligo)peptide can be prepared by cyclisation, catalysed by a cyclase. The invention further relates to a process for the enzymatic synthesis of an (oligo)peptide.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 25, 2020
    Assignee: ENZYPEP B.V.
    Inventors: Timo Nuijens, Peter Jan Leonard Mario Quaedflieg
  • Patent number: 10745713
    Abstract: Methods and compositions for deploying refuge seeds together with transgenic crop seeds are provided. The refuge seeds can be non-transgenic seeds of a similar variety to that of the transgenic crop seeds, or the refuge seeds can be a transgenic variety, but in either case lacking a transgenic trait conferring pest protection found in the transgenic crop seeds.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: August 18, 2020
    Assignee: Monsanto Technology LLC
    Inventors: Graham Head, Jay C. Pershing, John K. Soteres
  • Patent number: 10717992
    Abstract: The invention provides compositions and methods for regulating thermogenesis and muscle inflammation through modulation of Metrnl and/or Metrn activity and/or expression. Also provided are methods for preventing or treating metabolic disorders and muscle inflammation disorders in a subject through modulation of Metrnl and/or Metrn activity and/or expression. Further provided are methods for identifying compounds that are capable of treating metabolic disorders and muscle inflammation disorders by modulating Metrnl and/or Metrn activity and/or expression.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 21, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Rajesh R. Rao, Jonathan Z. Long
  • Patent number: 10718001
    Abstract: Disclosed is a host cell for producing a recombinant peptide, polypeptide or protein of interest, wherein the host cell includes at least 2 copies of a nucleic acid sequence encoding a poison protein; and to the use thereof for producing peptides, polypeptides or proteins of interest.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 21, 2020
    Assignee: DELPHI GENETICS
    Inventors: Cedric Szpirer, Jonathan Cavrenne, Benjamin Michel
  • Patent number: 10709758
    Abstract: Disclosed are synthetic peptides and peptide compositions, including peptide conjugates, that can ameliorate and/or block the cytotoxicity of Clostridium difficile toxin B(TcdB), and methods of their use for inhibiting the activity of Clostridium difficile toxin B(TcdB) and protecting against damage during Clostridium difficile toxin B(TcdB) disease, and/or for use as cell penetrating peptides for enhancing the delivery of particular heterogenous molecules into cells.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: July 14, 2020
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Jimmy D. Ballard, Jason L. Larabee